Foresite Capital Management III’s Verona Pharma VRNA Stock Holding History

Foresite Capital Management III’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$11.4M	Hold	1,111,112	–	–	29.98%	2
2022 Q2	$4.66M	Hold	1,111,112	–	–	16.89%	4
2022 Q1	$5.54M	Hold	1,111,112	–	–	16.89%	3
2021 Q4	$7.47M	Hold	1,111,112	–	–	18.9%	3
2021 Q3	$6.09M	Hold	1,111,112	–	–	8.44%	3
2021 Q2	$7.27M	Hold	1,111,112	–	–	7.7%	6
2021 Q1	$9.29M	Buy	+1,111,112	New	+$9.22M	8.16%	5
2020 Q4	–	Sell	-1,111,112	Closed	-$6.93M	–	9
2020 Q3	$6.93M	Buy	+1,111,112	New	+$7.68M	5.16%	8
2019 Q1	–	Sell	-206,663	Closed	-$1.99M	–	22
2018 Q4	$1.99M	Sell	206,663 -294,220	-59%	-$3.34M	0.65%	21
2018 Q3	$6.27M	Sell	500,883 -1,942	-0.4%	-$25.1K	1.38%	16
2018 Q2	$6.87M	Sell	502,825 -62,467	-11%	-$1.05M	1.48%	15
2018 Q1	$11.3M	Buy	565,292 +36,870	+7%	+$533K	2.46%	12
2017 Q4	$6.27M	Sell	528,422 -80,429	-13%	-$1.04M	1.76%	11
2017 Q3	$9.35M	Sell	608,851 -4,750	-0.8%	-$62.7K	2.57%	12
2017 Q2	$7.15M	Buy	+613,601	New	+$8.13M	2.34%	12

Other funds holding VRNA

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Foresite Capital Management III's VRNA Position: Q3 2022 in Review

Foresite Capital Management III held its Verona Pharma (VRNA) position steady in Q3 2022 at 1,111,112 shares worth $11.4M. The position accounts for 29.98% of the portfolio, ranked #2.

Foresite Capital Management III first reported a position in VRNA in Q2 2017 and has held it in 15 quarters since. 68 funds tracked by Wall St. Rank hold VRNA as of Q3 2022.

Foresite Capital Management III held 1,111,112 shares of Verona Pharma worth $11.4M as of Q3 2022.
Foresite Capital Management III left its Verona Pharma share count unchanged in Q3 2022.
Verona Pharma made up 29.98% of Foresite Capital Management III's portfolio in Q3 2022, its #2 holding.
Foresite Capital Management III first reported a position in Verona Pharma in Q2 2017 and has held it in 15 quarters since.
68 funds tracked by Wall St. Rank held Verona Pharma as of Q3 2022.

Based on Foresite Capital Management III's 13F filing for Q3 2022, filed 14 Nov 2022.